Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis.
We investigated the effects of fenofibrate, peroxisome proliferator-activated receptors (PPARs) agonist, on endothelial function in patients with hypertriglyceridemia. We administered placebo or fenofibrate 200 mg daily to 25 patients with hypertriglyceridemia for 8 weeks. This study was randomized, double-blind, placebo-controlled, crossover in design. Compared with placebo, fenofibrate significantly changed lipoprotein levels including non-HDL cholesterol and significantly improved the percent flow-mediated dilator response to hyperemia by 13 +/- 6% (P < 0.001) and lowered plasma levels of tumor necrosis factor-alpha by 13 +/- 3% (P < 0.001). Fenofibrate reduced fibrinogen and plasminogen activator inhibitor type 1 antigen levels by 17 +/- 3 and 10 +/- 3%, respectively (P < 0.001 and P = 0.014, respectively). However, fenofibrate did not significantly change plasma levels of nitrate, malondialdehyde, tissue factor activity, and serological markers of plaque stabilization. Fenofibrate significantly changed lipoprotein levels and improved the percent flow-mediated dilator response to hyperemia as well as lowered levels of tumor necrosis factor-alpha (TNF-alpha), fibrinogen, and plasminogen activator inhibitor type 1 antigen.
Kon Koh
Kwang
K
Department of Cardiology, Gil Heart Center, Gachon Medical School, 1198 Kuwol-dong, Namdong-gu, Incheon 405-760, Republic of Korea. Kwang@ghil.com
Yeal Ahn
Jeong
J
Hwan Han
Seung
S
Kyu Jin
Dong
D
Sik Kim
Hyung
H
Cheon Lee
Kyung
K
Kyun Shin
Eak
E
Sakuma
Ichiro
I
D000328:Adult; D015415:Biomarkers / Q000032:analysis; D002097:C-Reactive Protein / Q000032:analysis; D002320:Cardiovascular Physiological Phenomena; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology; D005260:Female; D011345:Fenofibrate / Q000008:administration & dosage*; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D015228:Hypertriglyceridemia / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D007249:Inflammation / Q000503:physiopathology; D008075:Lipoproteins, HDL / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011336:Probability; D011379:Prognosis; D012016:Reference Values; D018570:Risk Assessment; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D014666:Vasomotor System / Q000187:drug effects*
D015415:Biomarkers; D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein; D011345:Fenofibrate